Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 269 Results

August 9, 2022

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

August 5, 2022

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

July 21, 2022

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

June 7, 2022

Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

June 2, 2022

Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

May 25, 2022

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting

May 5, 2022

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

April 29, 2022

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

April 28, 2022

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

April 4, 2022

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

«...7 8910 11 12...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top